Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
22.12
-1.89 (-7.87%)
Feb 21, 2025, 4:00 PM EST - Market closed
Instil Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
49
Market Cap
144.35M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 138.00K | - | - |
| Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
TIL News
- 5 weeks ago - Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody - GlobeNewsWire
- 6 weeks ago - Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside - Benzinga
- 2 months ago - Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity - Seeking Alpha
- 5 months ago - Crude Oil Surges Over 1%; Instil Bio Shares Plunge - Benzinga
- 5 months ago - Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer - GlobeNewsWire
- 5 months ago - Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements - Seeking Alpha
- 6 months ago - Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody - GlobeNewsWire